Iñaki Argüelles

Iñaki Argüelles

Auto-generated profile, based on publicly available information

Iñaki Argüelles

Endocrinology and Nutrition Department, Son Espases University Hospital, Palma, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
JIJavier Ibáñez
Javier Ibáñez
EGEsteban M. Gorostiaga
Esteban M. Gorostiaga
AAAlicia M. Alonso-Martínez
Alicia M. Alonso-Martínez
LFLuis Forga
Luis Forga
IAIñaki Argüelles
Iñaki Argüelles
Mikel IzquierdoMikel Izquierdo
Mikel Izquierdo

1 August 2004 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MVM. Veitenhansl
M. Veitenhansl
KSK. Stegner
K. Stegner
FHF.-X. Hierl
F.-X. Hierl
CDC. Dieterle
C. Dieterle
HFH. Feldmeier
H. Feldmeier
HSH. Sekihara
H. Sekihara

19 November 2018 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
STSantiago Tofé
Santiago Tofé
IAIñaki Argüelles
Iñaki Argüelles
EMElena Mena
Elena Mena
GSGuillermo Serra
Guillermo Serra
MCMercedes Codina
Mercedes Codina
VPVicente Pereg
Vicente Pereg
Summary: Aims: To evaluate in a real‐world setting the effectiveness and tolerability of available GLP‐1 RA drugs in patients with type 2 diabetes after a prolonged follow‐up.Materials and methods: Observational, retrospective, single‐centre study in patients starting GLP‐1 RA therapy. Change in HbA1c, fasting plasma glucose (FPG) and body mass index (BMI) along with gastrointestinal (GI) adverse events and withdrawal from GLP‐1 RA therapy were evaluated. Lack of efficacy of GLP‐1 RA therapy according to prespecified goals was also measured.Results: A total of 735 patients were included, mean age 59.7 years, duration of diabetes 9.01 years, HbA1c 8.18% and BMI 38.56 kg/m2. Average follow‐up was 18.97 months (range 4.2‐39.09). All HbA1c (0.93%; P < 0.01), FPG (24 mg/dL; P < 0.01) and BMI (1.55 kg/m2; P < 0.05) were significantly reduced from baseline and maintained throughout follow‐up, regardless of prescribed GLP‐1 RA. GI adverse events were present in 13.81% of patients at first follow‐up visit, 37.07% of patients discontinued GLP‐1 RA treatment, and 38.63% did not meet efficacy goals.Conclusions: In a real‐world setting, GLP‐1 RA therapy is largely prescribed in severely obese patients with a long‐standing and poorly controlled diabetes. All prescribed GLP‐1 RAs significantly decreased HbA1c, FPG and BMI. GI adverse events affected a low proportion of patients. Inversely, a high proportion of patients did not meet efficacy goals and/or discontinued GLP‐1 RA treatment. Baseline characteristics of patients and lack of adherence may represent important issues underlying differences in effectiveness in real‐world studies versus randomized trials.

1 February 2010 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
SPSantiago Tofé Povedano
Santiago Tofé Povedano
IJIñaki Argüelles Jiménez
Iñaki Argüelles Jiménez
HFHonorato García Fernández
Honorato García Fernández
JJJulia Quevedo Juanals
Julia Quevedo Juanals
SMSergio Díaz Medina
Sergio Díaz Medina
VMVicente Pereg Macazaga
Vicente Pereg Macazaga

19 December 2013 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
JFJose C. Fernandez-Garcia
Jose C. Fernandez-Garcia
IMIsabel Mancha-Doblas
Isabel Mancha-Doblas
MOMaría Victoria Ortega-Jiménez
María Victoria Ortega-Jiménez
JRJosé Francisco Ruiz-Escalante
José Francisco Ruiz-Escalante
ICIgnasi Castells-Fusté
Ignasi Castells-Fusté
FTFrancisco Tinahones
Francisco Tinahones

30 November 2023 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
STSantiago Tofé
Santiago Tofé
IAIñaki Argüelles
Iñaki Argüelles
CÁCristina Álvarez
Cristina Álvarez
APAlvaro Tofé Povedano
Alvaro Tofé Povedano
ARAlessandra Repetto
Alessandra Repetto
VPVicente Pereg
Vicente Pereg
Objectives Neck recurrence of papillary thyroid cancer (PTC) is frequently detected after initial surgery. The management of these lesions may include rescue surgery (RS) or minimally invasive techniques in selected patients, but comparative studies evaluating the effectiveness and safety of these techniques are lacking. In this paper, we compared ultrasound-guided ethanol ablation (EA) in selected patients to RS in a matched cohort.Methods We retrospectively compared 41 patients and 41 matched PTC patients without known distant metastases, who underwent ultrasound-guided EA or RS (matched reference group), who had 63 and 75 thyroid bed and/or lymph node confirmed PTC recurrences during a median follow-up of 72.8 and 89.6 months, respectively. The primary outcome was time until structural recurrence, compared using Kaplan-Meier survival curves. The secondary outcomes included time until biochemical recurrence, plasma thyroglobulin (Tg) levels, American Thyroid Association (ATA) response-to-therapy categories by the last available observation, and treatment-derived complications in each group.Results No significant differences were found between the EA and RS groups for time until structural recurrence (log-rank test, P=0.94). The time until biochemical recurrence was also similar (P=0.51); and the plasma Tg concentration reduction and proportions of patients in the ATA reclassification categories were also similar. A significantly higher proportion of patients in the RS group presented treatment-derived complications (29.27% vs. 9.75%, P<0.05).Conclusion In this retrospective analysis, the treatment of PTC neck recurrence with EA in selected patients was comparable to RS in a matched reference group for the long-term risk of structural or biochemical relapse, but with a lower risk of treatment-derived complications. These results support the effectiveness and safety of this minimally invasive technique in the management of selected patients with recurrent PTC.